<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03523819</url>
  </required_header>
  <id_info>
    <org_study_id>CS1002-101</org_study_id>
    <nct_id>NCT03523819</nct_id>
  </id_info>
  <brief_title>A Study of CS1002 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase Ia/Ib, Open-Label, Dose-Escalation, and Dose-Expansion Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 as Monotherapy and in Combination With Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CStone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CStone Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, multiple dose, dose escalation phase I study to evaluate
      the clinical safety, tolerability, PK, and preliminary anti-tumor efficacy of CS1002.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 21, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Randomized for Part 3 of the study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From the day of first dose to 30 days after last dose of CS1002</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>CS1002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CS1002 intravenously at specified dose on specified days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CS1003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CS1003 intravenously at fixed dose on specified days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS1002</intervention_name>
    <description>Dose levels will be escalated following a modified 3+3 dose escalation scheme</description>
    <arm_group_label>CS1002</arm_group_label>
    <arm_group_label>CS1003</arm_group_label>
    <other_name>anti-CTLA 4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS1003</intervention_name>
    <description>Fixed dose at 200mg in combination with CS1002 on a specified dose level</description>
    <arm_group_label>CS1002</arm_group_label>
    <arm_group_label>CS1003</arm_group_label>
    <other_name>anti-PD1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with histologically or cytologically confirmed advanced or metastatic solid
             tumor(s) for which no effective standard therapy is available or tolerable.

          2. ECOG performance status of 0 or 1.

          3. Life expectancy â‰¥12 weeks.

          4. Subjects must have adequate organ function

          5. Use of effective contraception

        Exclusion Criteria:

          1. Known brain metastasis or other CNS metastasis that is either symptomatic or
             untreated.

          2. Subjects with active autoimmune diseases or history of autoimmune diseases.

          3. Subjects with immunodeficiency or receiving systemic steroid therapy or any other
             immunosuppressive therapy within 14 days prior to the first dose of CS1002.

          4. Subjects who received prior therapy with an anti-CTLA-4, anti-PD-1, anti-PD-L1,
             anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory
             T-cell receptor (e.g., OX-40, CD137).

          5. Subjects who had prior chemotherapy, targeted therapy, immunotherapy or any other anti
             cancer systemic treatment, within 14 days prior to the first dose of CS1002 or who has
             not recovered from adverse events due to prior therapy.

          6. Receipt of major surgical procedure, wide field of radiation, local radiotherapy or
             radioactive agents within specified time frame prior to the first dose of CS1002.

          7. Receipt of live vaccine within 28 days prior to the first dose of CS1002

          8. Use of traditional medicinal herbal preparations within 7 days prior to the first dose
             of CS1002.

          9. History of interstitial lung disease or non-infectious pneumonitis except for those
             induced by radiation therapies.

         10. Known history of HIV.

         11. Subjects with active Hepatitis B or C infection

         12. Subjects with active tuberculosis infection.

         13. Subjects with an active infection requiring systemic therapy.

         14. History of organ transplantation.

         15. History of alcoholism or drugs abuse.

         16. History of severe hypersensitivity reactions to other mAbs.

         17. Subjects with major cardiovascular diseases.

        For more information regarding trial participation, please contact at
        cstonera@cstonepharma.com
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wanmei Wang</last_name>
    <role>Study Director</role>
    <affiliation>CStone Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendie Yuan</last_name>
    <phone>+862161097678</phone>
    <email>cstonera@cstonepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Vincent's hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern Medical Day Care Centre</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ashford Cancer Centre Research</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 22, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

